Posted 3/4/2024, 11:30:00 AM
Melinta Therapeutics Emerges from Bankruptcy with New Strategy to Overcome Antibiotic Commercialization Challenges
- Melinta Therapeutics faced challenges commercializing good antibiotic products due to lack of incentives and high costs
- The company entered bankruptcy in 2019 and emerged with a new CEO focused on a long-term strategy
- The new strategy was to become experts at launching acute care products by understanding stakeholders
- Melinta leveraged this capability to license and launch other companies' products beyond antibiotics
- While advocating for better AMR reimbursement, Melinta diversified into adjacencies like antifungals to reduce risk